Top StoriesDepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease
By DepYmed, Inc. | May 23, 2022 DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
By DepYmed, Inc. | May 3, 2022 Role of a New Generation of PTP1B Inhibitors Against a Novel Intracellular Checkpoint in Cancer
By DepYmed, Inc. | March 10, 2022 DepYmed Appoints Peter Van Ess, Pharm.D., Ph.D. as VP of Early Development
By DepYmed, Inc. | August 5, 2021 Depymed, Inc. Announces $8.3 Million Financing
By DepYmed, Inc. | April 7, 2021 |
Shape Divider - Style triangle
Archived News
-
2018
-
2017
-
2016
-
2015
-
2014
<
>
December 24, 2015 (Newsday - Business)
DepYmed snags $100,000 to develop new breast cancer drug
December 23, 2015 (Northwell Health
Accelerate Long Island and the Long Island Emerging Technologies Fund Announce $50,000 Grant and $50,000 Investment in DepYmed
December 22, 2015 (InnovateLI)
DepYmed wins Accelerate funding
March 31, 2015 (Accelerate LI)
Accelerate LI Announces 14 Hottest Startups
March 17, 2015 (InnovateLI)
Clinical trials for DepYmed
February 17, 2015 (DepYmed, Inc)
DepYmed, Inc. Announces Appointment of New President and CEO
DepYmed snags $100,000 to develop new breast cancer drug
December 23, 2015 (Northwell Health
Accelerate Long Island and the Long Island Emerging Technologies Fund Announce $50,000 Grant and $50,000 Investment in DepYmed
December 22, 2015 (InnovateLI)
DepYmed wins Accelerate funding
March 31, 2015 (Accelerate LI)
Accelerate LI Announces 14 Hottest Startups
March 17, 2015 (InnovateLI)
Clinical trials for DepYmed
February 17, 2015 (DepYmed, Inc)
DepYmed, Inc. Announces Appointment of New President and CEO
Shape Divider - Style triangle
Publications
Shape Divider - Style triangle